Satellos Muscle Congress Presentation

Satellos Bioscience will present muscular dystrophy research at the World Muscle Society congress.

Satellos Bioscience Inc. is set to present at the 31st Annual Congress of the World Muscle Society (WMS) in Hiroshima, Japan from Sept. 29 to Oct. 3, 2026. The company is developing life-improving medicines to treat degenerative muscle diseases. The scientific posters at WMS will include a Phase 2a Dose Comparison and Exploratory Efficacy Study of Forazapadin (SAT-3247) in Ambulatory Boys with Duchenne Muscular Dystrophy. Satellos plans to submit an Investigational New Drug application and begin clinical research to investigate the use of ForAZapadin in facioscapulohumeral muscular dystrophy (FSHD) in the second half of 2026 and plans to pursue these opportunities in future clinical development.

Topics